Introduction
============

Osteoblasts are bone-specific, multifunctional cells that are responsible for bone formation through the synthesis of proteins of the bone extracellular matrix ([@bib18]). Because osteoblasts express the osteoclast differentiation factor RANKL (receptor activator of nuclear factor κ--B ligand), they also favor bone resorption ([@bib26]). In addition, osteoblasts are endocrine cells ([@bib17]). In agreement with the diversity of their functions, multiple extracellular cues can affect osteoblasts.

Parathyroid hormone (PTH) regulates *Rankl* expression through several mechanisms ([@bib25]). In one of them, PTH binds to its cognate receptor, PTH1R, a G protein--coupled receptor on osteoblasts, and enhances *Rankl* expression in a cAMP-dependent manner ([@bib19]). Ex vivo assays have suggested that CREB mediates the PTH regulation of *Rankl* expression ([@bib12]), but in vivo, however, inactivation of *Creb* in osteoblasts does not affect *Rankl* expression or bone resorption. Thus, the transcriptional mechanisms whereby PTH signaling in osteoblasts affects *Rankl* expression are not elucidated ([@bib16]). Another systemic cue affecting *Rankl* expression in osteoblasts is the sympathetic nervous system. Catecholamines, after their binding to another G protein--coupled receptor, the β~2~ adrenergic receptor, also use cAMP as a second messenger to enhance *Rankl* expression by recruiting the transcription factor ATF4 ([@bib10]). These observations raise the following question: How do two distinct regulatory signals that use the same second messenger elicit different transcriptional events in the same cell type?

Chromatin structure, which is influenced by posttranslational modifications of histone proteins around which the DNA is wrapped, is a major determinant of gene expression ([@bib15]; [@bib2]). Histone acetylation promotes gene transcription by relaxing the chromatin structure, whereas deacetylation of histones by histone deacetylases (HDACs) induces chromatin condensation and transcriptional repression ([@bib5]; [@bib28]; [@bib2]). Class II HDACs contain a poorly active catalytic domain and a long N-terminal extension to which transcription factors can bind. The existence of this domain has suggested that class II HDACs can link extracellular cues to the genome of a given cell ([@bib28]; [@bib14]).

One class II HDAC, HDAC4, prevents chondrocyte hypertrophy in part by inhibiting the activity of the transcription factor Runx2, a master gene of skeletogenesis, in proliferating chondrocytes ([@bib27]). Given the regulation of bone formation that Runx2 exerts through its expression in osteoblasts, this suggested that HDAC4 also regulates bone formation ([@bib18]).

We show here that, in vivo, HDAC4 does not inhibit Runx2 functions in osteoblasts but instead integrates PTH and sympathetic signaling. PTH signaling in osteoblasts favors *Rankl* expression by inducing, via the E3 ubiquitin ligase Smurf2, HDAC4 ubiquitination; this releases MEF2c, which can then activate *Rankl* expression. Conversely, the sympathetic tone promotes HDAC4 accumulation in the nucleus of osteoblasts and its interaction with ATF4. Thus, under the control of the sympathetic tone, HDAC4 favors *Rankl* and osteoclast differentiation. Lastly, HDAC4 does not inhibit Runx2 functions in osteoblasts in vivo because catecholamines disrupt the physical interaction between HDAC4 and Runx2. This study identifies HDAC4 as a link between two extracellular signals and the genome of osteoblasts.

Results and discussion
======================

HDAC4 inhibits *Rankl* expression in osteoblasts
------------------------------------------------

To study the functions of HDACs in osteoblasts, we asked which ones were expressed in these cells. *Hdac5* expression was twofold higher in bone than in any other tissue ([Fig. 1 B](#fig1){ref-type="fig"}). *Hdac4* expression was also higher in bone than in other tissues where it exerts important functions ([Fig. 1, A and B](#fig1){ref-type="fig"}; [@bib30]; [@bib6]; [@bib27]). Similar results were obtained at the protein level ([Fig. 1 C](#fig1){ref-type="fig"}).

![**HDAC4 and HDAC5 inhibit *Rankl* expression in osteoblasts.** (A) Expression of class IIa *Hdacs* in mouse osteoblasts. The expression of each gene is compared with the one of *Hdac5.* (B) *Hdac4* (right) and *Hdac5* (left) expression in various tissues. Expression of these genes in each tissue is compared with their expression in muscle. (C) HDAC4 and HDAC5 accumulation in different tissues. Anti-GAPDH was used as a loading control. (D and E) Histomorphometric analyses of vertebrae (D) and long bones (E) of *Hdac4~osb~^−/−^* (*n* = 7) and *Hdac5^−/−^* (*n* = 7) mice compared with *Hdac4^fl/fl^* (*n* = 8) or WT (*n* = 5) controls, respectively. BV/TV (%), percentage of bone volume over trabecular volume; NOsb/Bpm., number of osteoblasts per bone perimeter; BFR, bone formation rate; OcS/BS (%), percentage of osteoclast surface per bone surface. (F) Serum CTX levels in *Hdac4^fl/fl^* (*n* = 13), *Hdac4 ~osb~^−/−^* (*n* = 12), WT (*n* = 10), *Hdac5^−/−^* (*n* = 9), and *^+/+^Runx2-Cre* (*n* = 4). Results are expressed as fold changes compared with levels seen in *Hdac4^fl/fl^* mice. (G) *Rankl* expression in *Hdac4^fl/fl^* (*n* = 4), *Hdac4^−/−^* (*n* = 4; left), WT (*n* = 4), and *Hdac5^−/−^* (*n* = 4; right) osteoblasts. (H and I) *Opg* expression (H) and *Rankl/Opg* ratio (I) in *Hdac4^fl/fl^* (*n* = 4), *Hdac4^−/−^* (*n* = 4), WT (*n* = 4), and *Hdac5^−/−^* (*n* = 4) osteoblasts. For G--I, results are expressed as fold changes compared with levels seen in *Hdac4^fl/fl^* or WT osteoblasts. Results are given as means ± SEM. \*, P \< 0.05 by Student's *t* test. IB, immunoblot.](JCB_201403138_Fig1){#fig1}

We used *Hdac5^−/−^* mice to study HDAC5 functions in osteoblasts and generated mice lacking *Hdac4* in osteoblasts by crossing *Hdac4^fl/fl^* mice with mice expressing the *Cre* recombinase under the control of *Runx2* regulatory elements ([@bib23]). Before using *Hdac4~osb~^−/−^* mice, because *Runx2* expression is not restricted to osteoblasts, we verified that *Hdac4* had been efficiently deleted from osteoblasts but not from other cell types and that there was no overexpression of either *Hdac4* in the *Hdac5^−/−^* mice or of *Hdac5* in the *Hdac4~osb~^−/−^* mice ([Fig. S1, A and B](http://www.jcb.org/cgi/content/full/jcb.201403138/DC1){#supp1}).

Because HDAC4 inhibits Runx2 functions in chondrocytes, we expected that it would do the same in osteoblasts and that *Hdac4~osb~^−/−^* mice would display a high bone mass because of an increase in bone formation parameters. Instead, both *Hdac4~osb~^−/−^* and *Hdac5^−/−^* mice demonstrated a low bone mass phenotype affecting all bones tested. This was caused by a 50% increase in the bone surface covered by osteoclasts compared with control bones, whereas bone formation parameters were modestly affected ([Fig. 1, D and E](#fig1){ref-type="fig"}). This increase in bone resorption was caused by a marked increase in *Rankl* expression in *Hdac4^−/−^* and *Hdac5^−/−^* compared with control osteoblasts, whereas *Opg* expression was not changed to the same extent. As a result, the ratio of *Rankl*/*Opg* was increased over 50% in *Hdac4^−/−^* and *Hdac5^−/−^* compared with wild-type (WT) osteoblasts ([Fig. 1, G--I](#fig1){ref-type="fig"}). Expression of other regulatory genes and of *type I collagen* was normal in *Hdac4^−/−^* osteoblasts (Fig. S1 C). Thus, through their expression in osteoblasts, HDAC4 and HDAC5 inhibit *Rankl* expression and bone resorption. An explanation for the absence of HDAC4's influence on bone formation is proposed below (see [Fig. 4 H](#fig4){ref-type="fig"}). For the rest of this work, because of the cell-specific nature of the gene deletion, we studied *Hdac4~osb~^−/−^* mice.

HDAC4 inhibits osteoclast differentiation by preventing MEF2c to transactivate *Rankl*
--------------------------------------------------------------------------------------

To elucidate how HDAC4 inhibits *Rankl* expression in osteoblasts, we asked whether members of the MEF2 family of transcription factors regulate *Rankl* expression. There were two reasons to ask this question. The first one is the well-documented interaction of HDAC4 with MEF2 proteins in other cell types ([@bib30]). Second, there are three putative MEF2 binding sites in the mouse *Rankl* promoter that are conserved in all vertebrate species analyzed, and *Mef2a* and *Mef2c* are highly expressed in osteoblasts ([Fig. 2, A and B](#fig2){ref-type="fig"}).

![**HDAC4 prevents MEF2c to transactivate *Rankl.***(A) Putative MEF2 binding sites in the *Rankl* promoter of the mouse and other bony vertebrate species. Red letters indicate the core MEF2 binding sequence. (B) *Mef2* gene expression in WT osteoblasts (*n* = 3). Expression of each gene is compared with the expression of *Mef2a*. (C) Chromatin immunoprecipitation assay in mouse osteoblasts analyzing MEF2 binding to the *Rankl* promoter. NTC, no template control. (D) DNA cotransfection assays in COS cells with a *Rankl* promoter luciferase construct (p*Rankl-luc*) either WT or harboring a mutation in either one of the MEF2 binding sites alone or with a MEF2c expression vector. (E) Histomorphometric quantification the bone surface covered by osteoclasts and bone formation rate in vertebrae of *Mef2a^fl/fl^* (*n* = 5), *Mef2a~osb~^−/−^* (*n* = 5), *Mef2c^fl/fl^* (*n* = 6), and *Mef2c~osb~^−/−^* (*n* = 8; left) mice and long bones of *Mef2c^fl/fl^* (*n* = 6) and *Mef2c~osb~^−/−^* (*n* = 8) mice (right). BFR, bone formation rate; OcS/BS (%), percentage of osteoclast surface per bone surface. (F) Serum CTX levels in *Mef2a^fl/fl^* (*n* = 8), *Mef2a~osb~^−/−^* (*n* = 7), *Mef2c^fl/fl^* (*n* = 6), and *Mef2c~osb~^−/−^* (*n* = 7) mice. Results are represented as fold changes compared with levels seen in *Mef2c^fl/fl^* mice. (G) *Rankl* expression in *Mef2a^fl/fl^* (*n* = 8), *Mef2a~osb~^−/−^* (*n* = 7), *Mef2c^fl/fl^* (*n* = 13), and *Mef2c~osb~^−/−^* (*n* = 14) mice. Results are expressed as fold changes compared with levels seen in *Mef2c^fl/fl^* mice. (H) DNA cotransfection assays in COS cells of p*Rankl-luc* either WT or mutant for the MEF2 binding site 1, along with MEF2c and HDAC4 expression vectors. (I) Histomorphometric quantification of the bone surface covered by osteoclasts in the vertebrae of control (*n* = 5), *Mef2c~osb~^+/−^* (*n* = 4), *Hdac4~osb~^−/−^* (*n* = 4), and *Hdac4~osb~^−/−^*;*Mef2c~osb~*^+/−^ (*n* = 3) mice. (J) *Rankl* expression in control (*n* = 10), *Mef2c~osb~^+/−^* (*n* = 4), *Hdac4~osb~^−/−^* (*n* = 4), and *Hdac4~osb~^−/−^*;*Mef2c~osb~*^+/−^ (*n* = 5) calvaria. (K) Serum CTX levels of control (*n* = 6), *Mef2c~osb~^+/−^* (*n* = 3), *Hdac4~osb~^−/−^* (*n* = 4), and *Hdac4~osb~^−/−^*;*Mef2c~osb~*^+/−^ (*n* = 3) mice. In I and K, results are presented as fold changes compared with levels seen in control mice. (L) Histomorphometric analyses of BV/TV percentage in vertebrae of control (*n* = 9), *Mef2c~osb~^+/−^* (*n* = 4), *Hdac4~osb~^−/−^* (*n* = 5), and *Hdac4~osb~^−/−^*;*Mef2c~osb~*^+/−^ (*n* = 3) mice. Results are given as means ± SEM. \*, P \< 0.05 by Student's *t* test.](JCB_201403138_Fig2){#fig2}

Chromatin immunoprecipitation assays verified that MEF2 proteins could bind to each putative MEF2 binding site present in the mouse *Rankl* promoter ([Fig. 2 C](#fig2){ref-type="fig"}). In DNA cotransfection assays performed in COS cells, which do not express *Rankl*, an expression vector for *Mef2c* transactivated a construct containing a 3-kb-long fragment of the *Rankl* promoter driving the *luciferase* gene (p*Rankl-luc*); disrupting each of these three binding sites decreased the activity of this promoter fragment by ≥50% and abrogated MEF2c's ability to activate *pRankl-luc* ([Fig. 2 D](#fig2){ref-type="fig"}). The results provided in vitro evidence suggesting that MEF2 proteins are important to regulate *Rankl* expression in osteoblasts.

To determine whether what was observed in vitro exists in vivo, we generated mutant mice lacking *Mef2a* or *Mef2c* in osteoblasts only and verified that this manipulation had efficiently deleted *Mef2a* or *Mef2c* from osteoblasts but not from other cell types ([Fig. S2](http://www.jcb.org/cgi/content/full/jcb.201403138/DC1){#supp2}). Although mice lacking *Mef2a* in osteoblasts did not display any abnormalities of bone resorption, *Mef2c~osb~^−/−^* mice exhibited a significant decrease in the bone surface covered by osteoclasts in all bones analyzed ([Fig. 2 E](#fig2){ref-type="fig"}). Serum CTX levels were also significantly lower in *Mef2c~osb~^−/−^* than in *Mef2c^fl/fl^* mice, and *Rankl* expression was decreased nearly 50% in *Mef2c~osb~^−/−^* compared with control mice ([Fig. 2, F and G](#fig2){ref-type="fig"}).

The opposite influence of HDAC4 and MEF2c on *Rankl* expression along with the ability of HDAC4 to interact physically with MEF2c suggested that HDAC4 might inhibit *Rankl* expression by hampering the transactivating function of MEF2c. Indeed, in DNA cotransfection experiments, the ability of MEF2c to transactivate the *Rankl-luc* construct in COS cells was abrogated when an *Hdac4* expression vector was cotransfected ([Fig. 2 H](#fig2){ref-type="fig"}). In vivo, *Rankl* expression, serum CTX values, and bone mass were normal in *Hdac4~osb~^−/−^* mice lacking one allele of *Mef2c* in osteoblasts only ([Fig. 2, I--L](#fig2){ref-type="fig"}). Collectively, these results suggest the existence of an HDAC4 ┤ MEF2c →*Rankl* regulatory loop in mouse osteoblasts regulating osteoclast differentiation.

PTH favors *Rankl* expression through MEF2c by promoting HDAC4 proteasomal degradation
--------------------------------------------------------------------------------------

Next, we asked whether PTH signaling in osteoblasts promotes *Rankl* expression by disrupting this HDAC4 ┤ MEF2c →*Rankl* pathway. PTH increased the activity of *pRankl-luc* in ROS17/2.8 osteoblastic cells, and mutating the first MEF2 binding site in this promoter abrogated this effect of PTH ([Fig. 3 A](#fig3){ref-type="fig"}). Additionally, PTH triggered a marked decrease in HDAC4 accumulation in both the cytoplasm and the nucleus of mouse osteoblasts, without affecting MEF2c accumulation. This is different from what is observed after treatment of osteoblasts with PTH-related protein (PTHrP), a molecule that bears similarities to PTH and that signals through the same receptor ([Fig. 3, B--E](#fig3){ref-type="fig"}; [@bib21]), because PTHrP allows HDAC4 to move to the nucleus by inducing its dephosphorylation on S246 ([@bib20]). PTH induced the same dephosphorylation in HDAC4 in mouse osteoblasts ([Fig. 3 F](#fig3){ref-type="fig"}), but this could not explain our findings, as PTH induces a near complete disappearance of HDAC4 from osteoblast nuclei ([Fig. 3 C](#fig3){ref-type="fig"}).

![**PTH favors *Rankl* expression by disrupting the HDAC4--MEF2c interaction.** (A) DNA transfection assays in ROS17/2.8 cells using a *pRankl-luc* reporter construct for either WT (*pRankl-luc*) or mutated for each MEF2 binding site. Cells were treated with PTH or vehicle for 16 h. (B) Western blot analysis of total extracts from primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti--β-actin antibodies. (C) Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. (D) Immunofluorescence assays showing MEF2c localization in mouse primary osteoblasts treated with vehicle or PTH. (E) Immunofluorescence assays showing HDAC4 localization in mouse primary osteoblasts treated with vehicle, PTH, or PTHrP. (F) Immunoprecipitation of HDAC4 in WT primary osteoblasts treated with vehicle or PTH plus bortezomib. Proteins were analyzed by Western blotting using anti-HDAC4 or anti-HDAC4 phospho-S246 antibodies. (G) *Rankl* expression in primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib. Results are presented as fold changes compared with levels seen in vehicle-treated osteoblasts. (H) Immunoprecipitation of HDAC4 in primary osteoblasts treated with vehicle or PTH plus bortezomib. Proteins were analyzed by Western blotting using anti-HDAC4 or antiubiquitin antibodies. (I) Analysis of expression of E3 ubiquitin ligases in WT primary osteoblasts treated with PTH. Results for each gene are presented as fold change compared with levels seen in vehicle-treated osteoblasts. (J) *Rankl* expression in scrambled-, *Synv1*-, or *Smurf2* siRNA--transfected primary osteoblasts. Results are represented as fold changes compared with levels seen in scrambled siRNA--transfected cells. (K) *Rankl* expression in scrambled-, *Smurf2*-, or *Synv1* siRNA--transfected primary osteoblasts treated with vehicle or PTH. Results are presented as fold changes compared with levels seen in vehicle-treated scrambled siRNA--transfected cells. (L) Coimmunoprecipitation assay in ROS17/2.8 cells showing interaction between FLAG-Smurf2 and HA-HDAC4. Cytoplasmic extracts (CE) were immunoprecipitated after treatment with PTH or vehicle with an anti-FLAG antibody, and proteins were detected by Western blotting with anti-HA or anti-FLAG antibodies. (M) Analysis of *Rankl* expression in WT or *Ppr^+/−^;Smurf2^+/−^* primary osteoblasts treated with vehicle or PTH. (N) Western blot analysis of total extracts from primary osteoblasts treated with vehicle or PTH using anti-HDAC4 and anti--β-actin antibodies. Results are given as means ± SEM. \*, P \< 0.05 by Student's *t* test. IB, immunoblot; IP, immunoprecipitation.](JCB_201403138_Fig3){#fig3}

Because PTH does not decrease *Hdac4* expression in osteoblasts ([Fig. S3 A](http://www.jcb.org/cgi/content/full/jcb.201403138/DC1){#supp3}), we asked whether it induces proteasomal degradation of HDAC4 in osteoblasts. In support of this idea, the PTH-induced decrease of HDAC4 accumulation in osteoblasts was prevented by the addition of an inhibitor of proteasomal degradation, bortezomib ([Fig. 3, B and C](#fig3){ref-type="fig"}). Bortezomib also significantly decreased the ability of PTH to up-regulate *Rankl* expression in osteoblasts, and treating osteoblasts with PTH and bortezomib induced ubiquitination of HDAC4 ([Fig. 3, G and H](#fig3){ref-type="fig"}).

PTH up-regulated the expression of two E3 ubiquitin ligases that are highly expressed in osteoblasts *Smurf2* and *Synv1* ([Fig. 3 I](#fig3){ref-type="fig"}; [@bib24]). We tested whether Smurf2 and Synv1 are involved in PTH signaling in osteoblasts through siRNA knockdown experiments. In each experiment, we verified that we had efficiently decreased either *Smurf2* or *Synv1* accumulation, while not affecting *Hdac4* expression (Fig. S3, B and C). Decreasing Synv1 accumulation in osteoblasts increased *Rankl* expression and did not prevent PTH from inducing *Rankl* expression, whereas decreasing Smurf2 accumulation in mouse osteoblasts significantly lowered the expression of *Rankl* and hampered the ability of PTH to induce *Rankl* expression ([Fig. 3, J and K](#fig3){ref-type="fig"}). Three additional experimental evidences suggested that Smurf2 is a major target of PTH signaling in osteoblasts: first, Smurf2 interacts with HDAC4 only in the presence of PTH; second, PTH did not trigger HDAC4 ubiquitination in *Smurf2^−/−^* osteoblasts; and third, the PTH induction of *Rankl* expression was decreased nearly 50% in osteoblasts lacking one allele of *Ppr* (encoding the PTH receptor) and one allele of *Smurf2* ([Fig. 3, J--N](#fig3){ref-type="fig"}). These results indicate that PTH favors *Rankl* expression in osteoblasts, in part, by recruiting Smurf2 to ubiquitinate HDAC4. This abrogates the physical interaction between HDAC4 and MEF2c and allows MEF2c to activate the *Rankl* promoter.

The sympathetic tone favors *Rankl* expression by stabilizing HDAC4
-------------------------------------------------------------------

That PTH regulates *Rankl* expression in an HDAC4-dependent manner raised the hypothesis that another systemic regulator of *Rankl* expression in osteoblasts, the sympathetic nervous system ([@bib10]), might also recruit HDAC4 to achieve this function. To test whether this was the case, we treated mouse osteoblasts with isoproterenol (ISO), a surrogate of the sympathetic tone. Like PTH, ISO favored *Hdac4* expression ([Fig. 4 A](#fig4){ref-type="fig"}), but unlike PTH, ISO increased HDAC4 accumulation in the nucleus of osteoblasts and promoted its interaction with ATF4 ([Fig. 4, B and C](#fig4){ref-type="fig"}). ISO also decreased the phosphorylation of HDAC4 on S246, an event that favors HDAC4 translocation to the nucleus ([Fig. 4 D](#fig4){ref-type="fig"}). In vivo, mice lacking one allele of *Hdac4* and one allele of *Atf4* only in osteoblasts demonstrated a significant decrease in *Rankl* expression, circulating CTX values, and the bone surface covered by osteoclasts ([Fig. 4, E--G](#fig4){ref-type="fig"}). Of note, although ISO treatment of ROS17/2.8 osteoblastic cells or mouse osteoblasts increased the interaction between HDAC4 and ATF4, it disrupted in tandem the interaction between HDAC4 and Runx2. This latter observation provides an explanation as to why in the living animal, in which sympathetic signaling is constantly present, disruption of HDAC4 in osteoblasts does not affect Runx2-regulated bone formation ([@bib9]).

![**The sympathetic tone stabilizes HDAC4 to favor *Rankl* expression.** (A) Expression of *Hdac4* and in primary osteoblasts treated with vehicle or ISO for 2 h. Results are presented as fold changes compared with levels seen in vehicle-treated cells. (B) Immunofluorescence detection of HDAC4 in WT primary osteoblasts treated with vehicle or ISO. (C) Coimmunoprecipitation assay in ROS17/2.8 cells showing an interaction between FLAG-ATF4 and HA-HDAC4. Nuclear extracts (NE) were immunoprecipitated after ISO treatment with an anti-FLAG antibody, and proteins were detected by Western blotting with anti-HA or anti-FLAG antibodies. The numbers shown under each lane of the top blot represent the fold enhancement in intensity of the bands. (D) Immunoprecipitation of HDAC4 in mouse primary osteoblasts treated with vehicle or ISO. Proteins were analyzed by Western blot using anti-HDAC4 or anti--HDAC4-S246P antibodies. (E) Serum CTX levels in control (*n* = 8), *Hdac4~osb~^+/−^* (*n* = 3), *Atf4~osb~^+/−^* (*n* = 3), and *Atf4~osb~^+/−^; Hdac4~osb~^+/−^* (*n* = 3) mice, shown as fold changes compared with control levels. (F) *Rankl* expression in long bones of control (*n* = 8), *Hdac4~osb~^+/−^* (*n* = 3), *Atf4~osb~^+/−^* (*n* = 3), and *Atf4~osb~^+/−^;Hdac4~osb~^+/−^* (*n* = 3) mice. Results are presented as fold changes compared with levels seen in WT bones. (G) Histomorphometric quantification of the bone surface covered by osteoclasts in vertebrae of control (*n* = 8), *Hdac4~osb~^+/−^* (*n* = 3), *Atf4~osb~^+/−^* (*n* = 3), and *Atf4~osb~^+/−^;Hdac4~osb~^+/−^* (*n* = 3) mice. OcS/BS (%), percentage of osteoclast surface per bone surface. (H, left) Coimmunoprecipitation assay in ISO-treated ROS17/2.8 cells showing interaction between FLAG-Runx2 and HA-HDAC4. Nuclear extracts were immunoprecipitated with the anti-FLAG antibody. Purified proteins were detected by Western blotting with anti-HA or anti-FLAG antibodies. (right) Immunoprecipitation of Runx2 in mouse osteoblasts treated with vehicle or ISO. Proteins were analyzed by Western blotting using an anti-Runx2 or anti-HDAC4 antibodies. Results are given as means ± SEM. \*, P \< 0.05 by Student's *t* test. IB, immunoblot; IP, immunoprecipitation.](JCB_201403138_Fig4){#fig4}

This study reveals that *Hdac4*, through its expression in osteoblasts, prevents expression of *Rankl*, the major osteoclast differentiation factor, and serves as a bridge between two extracellular cues, regulating *Rankl* expression and the genome of osteoblasts ([Fig. 5](#fig5){ref-type="fig"}). On the one hand, PTH signaling in osteoblasts favors *Rankl* expression by inhibiting HDAC4 functions. To do that, PTH induces the ubiquitination of HDAC4 by enhancing the expression of an E3 ubiquitin ligase, *Smurf2*, in osteoblasts and promoting the interaction of Smurf2 and HDAC4. This frees MEF2c that can transactivate the *Rankl* promoter. Our results do not exclude in any way the fact that PTH also favors *Rankl* expression in osteoblasts by signaling in T lymphocytes ([@bib13]; [@bib25]). On the other hand, the sympathetic tone favors the accumulation of HDAC4 in osteoblasts and its interaction with ATF4, the only known transcriptional mediator of the sympathetic regulation of *Rankl* expression ([@bib10]). This mechanism is different from the PKA-induced proteolysis described by [@bib4] in cardiomyocytes. Although we cannot exclude that such a proteolysis occurs in osteoblasts, we note that if it were the case, ISO would prevent the expression of *Rankl* instead of increasing it.

![**Model of HDAC4 functions in osteoblasts.** PTH signaling favors HDAC4 (in gray) degradation through ubiquitination; this releases MEF2c, which can transactivate the *Rankl* promoter and favor bone resorption. The sympathetic tone favors HDAC4 accumulation, its translocation to the nucleus, its association with ATF4, and thereby, *Rankl* expression. The broken lines indicate that additional proteins yet to be identified are involved.](JCB_201403138_Fig5){#fig5}

Lastly, that compound heterozygous mice lacking one allele of *Ppr* in osteoblasts and one allele of *Mef2c* also in osteoblasts have normal bone resorption parameters (unpublished data) argues against the existence of a cross talk between the two arrows of the current models. The different mechanisms whereby PTH and the sympathetic tone use HDAC4 as an intermediary step to fulfill their functions in osteoblasts suggest that these two extracellular cues must recruit different intracellular signaling molecules. Further biochemical studies will help clarify this aspect of PTH and sympathetic signaling in osteoblasts.

Materials and methods
=====================

Mouse generation
----------------

As previously reported, *Hdac5^−/−^* mice were generated by fusing in frame the lacZ cDNA and neomycin resistance cassette under the control of the phosphoglycerate kinase promoter to the 5′ region of exon 3, therefore placing a *β-galactosidase* (*β-gal*) reporter gene under the control of endogenous *Hdac5* promoter (provided by E. Olson and R. Bassel-Duby, University of Texas Southwestern Medical Center, Dallas, TX; [@bib6]). *Hdac4* floxed mice were generated by the insertion of loxP sites, flanking exon 6, which results in an out-of-frame mutation in the *Hdac4* allele (provided by E. Olson and R. Bassel-Duby; [@bib22]). *Hdac4~osb~^−/−^* mice were generated by intercrossing *Hdac4^fl/fl^* mice with *Runx2-Cre* transgenic mice ([@bib23]). *Mef2a* and *Mef2c* conditional alleles were generated by flanking exon 2 with loxP sites of each gene (provided by E. Olson and R. Bassel-Duby; [@bib3]; [@bib1]). *Mef2a~osb~^−/−^* and *Mef2c~osb~^−/−^* mice (C57BL/6J) were generated by intercrossing *Mef2a^fl/fl^* or *Mef2c^fl/fl^* mice and *Runx2-Cre* transgenic mice. *Hdac4~osb~^−/−^;Mef2c~osb~^+/−^* mice were obtained from crosses between F2 generation *Hdac4~osb~^+/−^;Mef2c~osb~^+/−^* and *Hdac4^fl/fl^* or *Hdac4~osb~^+/−^* and *Hdac4~osb~^+/−^;Mef2c~osb~^+/−^* mice. The *Atf4* conditional allele was generated by placing a floxed neomycin cassette upstream of exon 2 and a loxP site downstream of exon 3 ([@bib29]). *Hdac4~osb~^+/−^;Atf4~osb~^+/−^* mice were generated by crossing *Atf4^fl/fl^* or *Atf4^fl/+^* mice with *Hdac4~osb~^+/−^* mice. *Hdac4^fl/fl^*, *Mef2a^fl/fl^*, or *Mef2c^fl/fl^* mice littermates were used for the control mice for *Hdac4~osb~^−/−^*, *Mef2a~osb~^−/−^*, and *Mef2c~osb~^−/−^* mice, respectively. Floxed mice and *Cre*-expressing mice littermates (control in the figures) were used as control mice for *Hdac4~osb~^−/−^;Mef2c~osb~^+/−^ and Hdac4~osb~^+/−^;Atf4~osb~^+/−^. Ppr*^fl/fl^ mice were provided by H. Kronenberg (Massachusetts General Hospital, Boston, MA). Mice genotypes were determined by PCR. All animal procedures were approved by the Columbia University Medical Center Institutional Animal Care and Use Committee and conform to the relevant regulatory standards.

Bone histomorphometry
---------------------

Lumbar vertebrae or tibia dissected from 2- or 3-mo-old male mice were fixed for 24 h, dehydrated with graded concentrations of ethanol, and embedded in methyl methacrylate resin according to standard protocols. Von Kossa/Van Gieson, toluidine blue, and tartrate-resistant acid phosphatase stainings were used to measure bone volume over tissue volume (BV/TV) and osteoblast and osteoclast numbers and surface, respectively. Bone formation rates were assessed after calcein double labeling. Calcein (Sigma-Aldrich) was dissolved in calcein buffer (0.15 M NaCl and 2% NaHCO~3~) and injected twice at 0.125 mg/g body weight on days 1 and 4, and mice were killed on day 6. Vertebrate pictures for Von Kossa/Van Gieson were obtained using a microscope (DM4000B; Leica) equipped with a camera (DFC300 FX; Leica) using a 2.5× magnification. Images were acquired with Fire software (Leica), and BV/TV was analyzed using ImageJ software (National Institutes of Health). All quantifications were acquired with a fluorescent microscope (DMLB; Leica) equipped with a charge-coupled device camera (DXC-390; Sony) at 40× magnification. Analysis of the parameters was performed using OsteoMeasure Analysis system (OsteoMetrics).

Cell-based assays
-----------------

Primary osteoblasts were isolated from calvaria of 2-d-old mice as described previously ([@bib8]; [@bib11]). In brief, calvaria were sequentially digested for 5 and 60 min at 37°C in α-modified MEM (α-MEM; Life Technologies) containing 1 mg/ml collagenase type 2 (Worthington Biochemical Corporation) and 0.25% trypsin-EDTA (Life Technologies). Cells of the first digest were discarded, whereas cells released from the second digestion were plated in α-MEM and 10% fetal bovine serum. For in vitro gene inactivation, floxed osteoblasts were divided into two groups and infected with either GFP- or Cre-expressing adenovirus (University of Iowa). For siRNA transfections, osteoblasts were transfected with siRNA pools (On-TARGETplus; Thermo Fisher Scientific) according to the manufacturer's instructions. For immunofluorescence, cells were trypsinized, replated after 2 d of culture, and left in regular media conditions for 1 d. On experiment day, cells were washed twice with PBS and treated with indicated amounts of PTH (1--34) (10 nM; ProSpec), PTHrP (1--36) (10 nM; Bachem), ISO (10 µM; Sigma-Aldrich), and bortezomib (25 nM; Selleckchem) for 2 h. Immunofluorescence was performed using a standard protocol. Pictures were obtained on a confocal microscope (LSM 710; Carl Zeiss) at 63× magnification. For gene expression, osteoblasts were cultured in α-MEM containing 10% FBS supplemented with 5 mM β-glycerophosphate and 100 µg/ml ascorbic acid for 10 d. Cells were fasted in serum-free media for 16 h and treated with 10 nM PTH, 10 µM ISO, or 25 nM bortezomib for 2 h. Cells were then collected in TRIZOL (Invitrogen), and RNA isolation, cDNA preparation, and real-time PCR analysis were performed following standard protocols. In brief, total RNA was extracted, DNase I treated, and reverse transcribed with random primers using the cDNA synthesis kit (SuperScript III; Invitrogen). The cDNA samples were then used as templates for quantitative PCR analysis that was performed using the Taq SYBR Green Supermix with ROX (Bio-Rad Laboratories) and specific primers ([Table S1](http://www.jcb.org/cgi/content/full/jcb.201403138/DC1){#supp4}) on a CFX Connect apparatus (Bio-Rad Laboratories). Expression levels of all quantitative PCR reactions were normalized using *hprt* expression levels as an internal control for each sample.

Molecular biology and biochemistry
----------------------------------

For DNA cotransfection assays, COS cells were cultured in DMEM supplemented with 10% FBS. Cells were transfected with 100 ng pCMV14-FLAG-MEF2c or 10 ng pCDNA3.1-HA-HDAC4 expression vectors, pGL3-Basic-*Rankl* (*pRankl-luc*), pGL3-Basic*-Rankls1* (*pRankls1-luc*), pGL3-Basic*-Rankls2* (*pRankls2-luc*), or pGL3-Basic*-Rankls3* (*pRankls3-luc*; 5 ng), and *pCMV--β-gal* reporter vectors. DNA transfections were performed in ROS17/2.8 cells cultured in DMEM F12 (1:1) supplemented with 10% FBS. Cells were transfected with 5 ng *pRankl-luc* or 5 ng *pRankls1-luc* and 200 ng *pCMV--β-gal* reporter vectors. 32 h after transfection, cells were washed with PBS and treated with serum-free media containing either 10 nM PTH or vehicle for the indicated times. Luciferase and β-gal assays were performed using standard procedures. For coimmunoprecipitation assays, ROS17/2.8 cells were transfected with 6 µg pCMV5-FLAG-ATF4, 6 µg pCMV5-FLAG-Runx2, 6 µg pCMV5-Smurf2, or pCDNA3.1-HA-HDAC4 (2 µg). 48 h later, cells were washed with PBS and treated with media containing 0.1% FBS and 10 nM PTH, 25 nM bortezomib, or 10 µM ISO for 2 h. Cells were lysed in hypotonic buffer and disrupted by Dounce homogenizer. The cytosolic fraction was separated from the pellet by centrifugation at 4°C. The nuclear-soluble fraction was obtained by incubation of the pellet in high-salt buffer to get a final NaCl concentration of 300 mM. Tagged proteins from each fraction were immunoprecipitated with anti-Flag M2 overnight. The next day, protein G--agarose beads were added and incubated for 2 h at 4°C. Each immunoprecipitation was washed five times with TGEN 150 buffer (20 mM Tris, pH 7.65, 150 mM NaCl, 3 mM MgCl~2~, 0.1 mM EDTA, 10% glycerol, and 0.01% NP-40), and proteins were eluted with Laemmli buffer and boiled for 10 min. For immunoprecipitation in primary osteoblasts, cells were lysed with 20 mM Tris, pH 7.65, 150 mM NaCl, and 1% NP-40 in and disrupted by Dounce homogenizer. The soluble fraction was incubated with indicated antibodies overnight at 4°C. The next day, protein G--agarose beads were added and incubated for 2 h at 4°C. Each immunoprecipitation was washed five times with TGEN 150 buffer (20 mM Tris, pH 7.65, 150 mM NaCl, 3 mM MgCl~2~, 0.1 mM EDTA, 10% glycerol, and 0.01% NP-40), and proteins were eluted with Laemmli buffer and boiled for 10 min.

Antibodies used in this study are mouse monoclonal anti-FLAG (F3165; Sigma-Aldrich), rabbit polyclonal anti-MEF2c (ab79436; Abcam), rabbit polyclonal anti-MEF2 (sc-313X; Santa Cruz Biotechnology, Inc.), rabbit polyclonal anti-HDAC4 (sc-11418; Santa Cruz Biotechnology, Inc.), rabbit monoclonal anti-HA (C29F4; Cell Signaling Technology), rabbit polyclonal anti-HDAC5 (2082; Cell Signaling Technology), rabbit polyclonal anti--phospho-HDAC4S-246 (provided by T.P. Yao, Duke University School of Medicine, Durham, NC; [@bib7]), rabbit monoclonal anti-GAPDH (14C10; Cell Signaling Technology), and mouse monoclonal antiubiquitin (3936; Cell Signaling Technology). DAPI was included in the mounting media (Electron Microscopy Sciences).

Chromatin immunoprecipitation
-----------------------------

Mouse osteoblasts were washed twice with PBS and cross-linked with 1.1% formaldehyde for 10 min at 37°C. Cross-linking was stopped by 125 mM glycine with gentle rocking. Cells were washed with PBS containing 0.25 mM PMSF, nuclear extracts were prepared, and each sample was sonicated to obtain sheared fragments of 200--800 bp. Samples were precleared with normal rabbit IgG with incubation for 1 h and agarose G beads for 2 h at 4°C. An anti-MEF2 antibody was added to cleared lysates and incubated overnight at 4°C. The next day, agarose protein G beads were blocked with 200 µg/ml salmon sperm DNA and 1 mg/ml BSA for 1 h at 4°C. Lysates were incubated with blocked beads for 2 h at 4°C and washed once in low salt buffer, twice in high salt, twice in LiCl buffer, and twice in Tris EDTA buffer. Washed beads were eluted in elution buffer by incubating at 37°C for 2 h. The DNA was reverse cross-linked by incubating all samples at 65°C for 6 h. After DNA extraction, PCR analysis was performed on chromatin immunoprecipitated material with specific primers (for binding sites 1 and 2, 5′-GGGTCCTCTTAGCACCTTGAC-3′ and 5′-GACATGCTTAGATGAAAAATG-3′; for binding site 2, 5′-GTGGCATGGGTTTATTTATT-3′ and 5′-TCCTGAGTGCTGGGATTAAA-3′; for binding site 3, 5′-AGGCTCTCTTGTGACCTAGAG-3′ and 5′-CACACTTCCCACTTTGCCCAC-3′; for 3′UTR, 5′-CTAGAATTTCCCCAAGTCTTC-3′ and 5′-GGCTGGCCCCTATCCTTTGC-3′) designed to detect the Mef2 binding sites within the mouse *Rankl* promoter.

Statistical analyses
--------------------

Results are given as means ± SEM. Statistical analyses were performed using unpaired, two-tailed Student's *t* test. In all figures, error bars represent SEM, and asterisks represent P \< 0.05.

Online supplemental material
----------------------------

Fig. S1 shows osteoblast-specific deletion of *Hdac4*. Fig. S2 shows osteoblast-specific deletion of *Mef2a* and *Mef2c*. Fig. S3 shows that PTH regulation of *Hdac4* expression is independent of *Smurf2* or *Synv1* inactivation. Table S1 shows primers used in this study. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201403138/DC1>.
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